About Chlorella
Single-celled green algae (Chlorella vulgaris and C. pyrenoidosa are most studied; C. sorokiniana also commercial). Two distinct evidence stories: (1) Lipid and blood pressure — Fallah 2018 meta-analysis (19 RCTs, n=797; PMID 29037431) reported significant SBP reduction (−4.5 mmHg) at >4 g/day for ≥8 weeks. Sherafati 2022 dose-response lipid meta-analysis (10 RCTs, n=539; PMID 35331862) found LDL-C and TC reductions specifically at ≤1.5 g/day, with diminishing/no benefit at higher doses — opposite dose-response from BP. Trial quality is mixed (mostly small, single-center Iranian/Japanese studies). (2) Detox / heavy-metal binding — the dominant marketing claim. RCT evidence in humans is essentially absent; most data is in-vitro and animal models showing arsenic, lead, and mercury chelation. The one cited human pilot (Merino 2019, n=6, dental amalgam) used a chlorella+Fucus+aminosulphurate combo, no placebo, non-RCT — inadequate to support 'heavy-metal detox' marketing. Contains methylcobalamin and adenosylcobalamin (bioactive B12 forms — unlike spirulina's pseudo-B12, per Watanabe 2002 PMID 12656203 and Bito 2016 PMID 27776413), but content varies <0.1–415 µg/100g by strain/conditions — not a reliable B12 source. Vitamin K content can cause warfarin resistance (case report: PMID 8777808). Source quality matters: lower-grade products can be contaminated with heavy metals or microcystin. No established RDA/UL.
What Chlorella supports
- Modest LDL/TC reductions in meta-analysis at lower doses (≤1.5 g/day); BP reduction at higher doses (>4 g/day)
- 'Detox' and heavy-metal-binding claims are not supported by human RCTs at supplement doses
How much Chlorella to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1500–8000
mg
Dose response is endpoint-specific: lipid effect (LDL/TC reduction) peaks at LOW doses ≤1.5 g/day per Sherafati 2022 dose-response meta-analysis; BP effect requires HIGHER doses >4 g/day for ≥8 weeks per Fallah 2018. Cell-wall-broken (cracked) forms have better protein/nutrient bioavailability than intact-cell-wall preparations.
Clinical evidence
Limited clinical evidence. Lipid: Sherafati 2022 dose-response meta-analysis (10 RCTs, n=539; PMID 35331862) — LDL/TC benefit at ≤1.5 g/day. BP: Fallah 2018 meta-analysis (19 RCTs, n=797; PMID 29037431) — SBP reduction at >4 g/day for ≥8 weeks. Detox/heavy-metal claims lack human RCT support — mostly in-vitro and animal data. Warfarin interaction documented (PMID 8777808).
Examine.com